01 September 2018 : Laboratory Research
[Retracted: 25 Mar 2021] Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
Fengli Zhang12BCDEF, Huixiao Chen2BCDEF, Jing Du2BCF, Bin Wang2BD, Lixiao Yang2ACDEFG*DOI: 10.12659/MSM.909745
Med Sci Monit 2018; 24: LBR6093-6101
Abstract
BACKGROUND: Ovarian cancer is considered one of the lethal cancers responsible for high mortality and morbidity across the world. The prognosis and the survival rate of ovarian cancer is far from decent. Cysteine-rich 61 (Cyr61) also known as CCN1, is a member of CCN-family of growth factors, reported to be significantly overexpressed in several malignancies which include, but are not limited to, ovarian cancer. Recent studies have revealed that women with type 2 diabetes mellitus have an elevated risk of ovarian cancer. Hence, administration of an antidiabetic drug with anticancer effects such as metformin may act as an effective therapeutic regime against ovarian cancer.
MATERIAL AND METHODS: Cell viability and apoptosis were examined by MTT and Annexin V/PI double staining respectively. Cell migration was determined by Boyden Chamber assay. Transient knockdown of Cyr61 in ovarian cancer cells was achieved by transecting the cells with siRNA for Cyr61using Lipofectamine 2000.
RESULTS: Our results indicated that treatment of ovarian cancer cells with metformin caused significant downregulation of Cyr61 protein expression levels ultimately favoring apoptosis. Transient knockdown of Cyr61 resulted in the inhibition of cell proliferation and migration. This was also associated with the concomitant downregulation of pAkt and pmTOR confirming the role of Cyr61 as an upstream modulator of Akt signaling. Conversely the extracellular supplementation of recombinant Cyr61 attenuates the cytotoxic properties of metformin in ovarian cancer cells.
CONCLUSIONS: Taken together, we concluded that metformin exhibits anticancer effects and Cyr61 acts as a direct target for metformin in ovarian cancer cells.
Keywords: Retracted Publication
Retraction note
- Download PDF
- Order reprints
- Export Article
- Related articles
- Share by email
- Metrics
1,199 2
Editorial
01 February 2025 : Editorial
Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-SmokersDOI: 10.12659/MSM.948255
Med Sci Monit 2025; 31:e948255
In Press
Clinical Research
Surgical Efficacy in Varicocele Ligation with Ephedrine-Assisted Blood Pressure ControlMed Sci Monit In Press; DOI: 10.12659/MSM.946234
Clinical Research
Retrospective Study to Compare Injury Patterns and Associations in 170 Patients Following Electric Scooter ...Med Sci Monit In Press; DOI: 10.12659/MSM.947155
Review article
Hydrogels in Oral Disease Management: A Review of Innovations in Drug Delivery and Tissue RegenerationMed Sci Monit In Press; DOI: 10.12659/MSM.946122
Clinical Research
Procedure Dynamics in Transfemoral vs Transradial Cerebral Angiography: A Retrospective StudyMed Sci Monit In Press; DOI: 10.12659/MSM.947603
Most Viewed Current Articles
17 Jan 2024 : Review article 6,968,724
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 701,829
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 25,567
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 20,099
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912